Pioglitazone HCI (Thiazolidinediones/ glitazones)

• Improves glycemic control while reducing circulating insulin levels.
• Significantly affects Glycated Haemoglobin (HbA1c) and FPG (Fasting Plasma Glucose) while producing beneficial effects on serum lipids.

Metformin HCI (Biguanides)

• Effectively reduces BMI and insulin resistance in hyperinsulinemic obese adolescents and children.

Combination:

• The insulin sensitizers, both metformin, and glitazones are mainly used in subjects with type 2 diabetes who are obese.
• Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity, and improved insulin secretion also.
• Metformin and pioglitazone were useful in reducing postprandial hyperglycemia.
• Mean cholesterol decreased significantly in groups treated with metformin and pioglitazone.
• HDL-cholesterol increased with pioglitazone. Insulin resistance decreased significantly with metformin and pioglitazone, and β cell function also showed improvement.